Surrozen reports Q2 2026 results, plans SZN-8141 IND filing by Q3 endAug 6Quarterly updateSurrozen, Inc./DE
Roche's lebrikizumab asthma trial posts results; new faricimab trial planned for eye diseaseJul 2Weekly roundup, 2 itemsfaricimablebrikizumab
Sign inSign in